AI-enabled diagnostic and treatment platform Paige (formerly Paige.AI) has announced a $100 million Series C round led by Casdin Capital and Johnson & Johnson Innovation. The startup's prior backers and other unnamed funds also took part in the raise.
Paige uses computational and digital pathology to help oncologists and pathologists make decisions faster, more accurately and at a lower...
This morning the AI-enabled diagnostic and treatment platform Paige, formerly called Paige.AI, announced a $45 million Series B funding round. The latest raise was led by Healthcare Venture Partners with participation from Breyer Capital, Kenan Turnacioglu and other funders.
Today the company has $70 million in investments. This latest round comes roughly two years after the company closed a $25...
FDA fast-tracks cancer AI. This morning Paige.AI, a pathology company that uses artificial intelligence for diagnosis and development, was granted a Breakthrough Device designation by the FDA. Page.AI has been working with Memorial Sloan Kettering Cancer Center to digitize pathology slide and create a pathology dataset.
“Paige.AI is focused on providing artificial intelligence tools to...
MDLive has brought on Dan Monahan as its new CFO and COO. Monahan, who will provide oversight for the company’s finance, accounting, treasure, tax, revenue cycle management, analytics and operations, comes from a CFO and SVP of operations position at Change Healthcare, and previously led similar financial and operational roles at Sprint, Nortel Networks, SITA, CDC Software and EMS Technologies.
“...
Dentist gone digital. On Friday CareStack, a cloud-based technology company that caters to the dental industry, announced that it scored $16 million in funding. The round was led by Accel, F-Prime Capital Partners, and Eight Roads Ventures.
“CareStack is helping dental practices across the country gain better control of their operations, which is leading to better patient care. We are excited to...
Paige.AI, a health technology company that applies artificial intelligence to pathology for cancer diagnosis and treatment, recently announced it landed $25 million in Series A funding, led by Jim Breyer of Breyer Capital.
“Patients deserve and need an accurate diagnosis as quickly as possible, yet our current methods are time-consuming, expensive and subjective,” Dr. David Klimstra, cofounder...
